The way I see it is as follows in terms of the MPS programs:MPS...

The way I see it is as follows in terms of the MPS programs:

• MPS VI We are at Phase 2/3 for Europe and US....The IND will most likely be Q1 2021, this trial should go for a year and then we have the read out

• MPS I has also been badged as orphan status. I think this is more of an exploratory trial in Adelaide. Based on the strength of the MPS VI (P2/P3 combined - Europe and US) and on success of MPS I Phase 2 (Adelaide), this may be enough to qualify us to be licensed to use iPPS to tackle both strains of MPS (I and VI) and garner revenue in this area.

I might have this wrong, but I think thats the gist.

So yes Mixed Bag, you are right, 10 patients for the Adelaide P2 Trial wouldn't be enough on its own in my view. But combining this with the main MPS (VI) trial that will start next year is the main pathway.